Our focus is helping researchers achieve more and use less. We create novel, game-changing tools that provide superior quantitative data with reduced cost and process.
At Nanomedical Diagnostics, our goal is to help you fully characterize and explore your biomolecules to make better decisions earlier. We have developed a breakthrough electrical assay based on proprietary Field Effect Biosensing (FEB) technology that provides real-time label-free kinetic binding and affinity data. Unique graphene biosensors at the heart of the assay deliver highly-sensitive biophysical characterization of small molecules ≥1 Da in complex media such as DMSO, using unprecedentedly small amounts of sample, making the platform a novel orthogonal option for drug discovery hit validation and lead optimization.
As the world’s only provider of graphene biosensors, our mission is to transform the healthcare industry with innovative new products that enable cutting-edge life science research, drug discovery applications, and diagnostic and health monitoring platforms. Our next system, AGILE R200, will enable full automation of extremely high-throughput kinetic, affinity, and concentration data simultaneously, and is slated to launch in early 2018.